Anzeige
Mehr »
Login
Donnerstag, 13.08.2020 Börsentäglich über 12.000 News von 644 internationalen Medien
Neuer Wolfram-Player legt los! Jetzt einsteigen...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 936386 ISIN: US8006771062 Ticker-Symbol: GBY 
Tradegate
12.08.20
19:02 Uhr
9,805 Euro
-0,545
-5,27 %
1-Jahres-Chart
SANGAMO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SANGAMO THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,7839,98012.08.
9,80910,01412.08.

Aktuelle News zur SANGAMO THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SANGAMO THERAPEUTICS Aktie jetzt für 0€ handeln
06.08.Sangamo Therapeutics +3.1% despite Q2 miss26
06.08.Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2020 Results - Earnings Call Transcript42
05.08.SANGAMO THERAPEUTICS, INC - S-8, Securities to be offered to employees in employee benefit plans10
03.08.Sangamo and Novartis partner on gene therapies for autism26
31.07.Novartis Pays $75M to Get Hands on Sangamo's Zinc Fingers for Drug R&D39
31.07.SANGAMO THERAPEUTICS, INC - 8-K, Current Report10
30.07.Novartis turns to Sangamo with a $795M-plus deal aimed at using zinc finger tech for the neuro pipeline24
30.07.Sangamo, Novartis Partner to Develop Gene Therapies for Autism14
30.07.Sangamo, Novartis Make Gene Therapy Deal for Brain Disorders10
30.07.Novartis, Sangamo team up on genetic meds for autism in $75M deal14
30.07.Sangamo teams up with Novartis in neurodevelopmental disorders14
30.07.Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders392Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability Sangamo will receive a $75M...
► Artikel lesen
13.07.Sangamo 2H 2020 Preview41
26.06.Inovio adds two to the leadership team; Adrian Woolfson is out at Sangamo62
25.06.Sangamo splits the R from the D in a reorganization - and bids chief farewell27
24.06.SANGAMO THERAPEUTICS, INC - 8-K, Current Report16
24.06.Sangamo R&D chief hits the exit as it splits R&D into separate units11
18.06.Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial58
18.06.Pfizer/Sangamo gene therapy shows positive effect in early-stage hemophilia A study63
18.06.BRIEF-Pfizer, Sangamo Therapeutics Announce Data From Phase 1/2 Alta Study Of Giroctocogene Fitelparvovec31
Seite:  Weiter >>
82 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5